The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
An Orally-Administered Nanotherapeutics with Carbon Monoxide Supplying for Inflammatory Bowel Disease Therapy by Scavenging Oxidative Stress and Restoring Gut Immune Homeostasis
Abstract
Traditional drug-based treatments for inflammatory bowel disease (IBD) have significant limitations due to their potential off-target systemic side-effects. Currently, there is a lack of understanding on how to effectively address excessive oxidative stress, dysregulated immune homeostasis, and microbiota dysbiosis within the IBD microenvironment. Herein, we introduce a nanotherapeutic approach, named LBL-CO@MPDA, for IBD treatment. LBL-CO@MPDA is an orally administered formulation that supplies carbon monoxide (CO) for therapeutic purposes. To create the LBL-CO@MPDA nanocomposite, we developed a layer by layer (LBL) self-assembly strategy where we coated chitosan/alginate polyelectrolytes onto the surface of CO prodrug-loaded mesoporous polydopamine nanoparticles (CO@MPDA). Benefiting from the negatively charged surface of the LBL coating, it allows for targeted accumulation of LBL-CO@MPDA specifically onto the positively charged inflamed colon lesions through electrostatic interactions. Furthermore, in the oxidative microenvironment of the inflamed colon, the nanotherapeutic system releases CO in a responsive manner. Interestingly, CO@MPDA ameliorates inflammatory conditions by MPDA-mediated ROS-scavenging and CO-mediated immunomodulation. CO-supplying activates heme oxygenase-1, leading to macrophage M2 polarization via the Notch/Hes1/Stat3 signaling pathway, while suppressing the inflammatory response by down-regulating the p38 MAPK and NF-κB (p50/p65) signaling pathways. In the mice model of dextran sulfate sodium (DSS)-induced IBD, LBL-CO@MPDA effectively reverses the pro-inflammatory microenvironment and restores gut barrier functions through multiple mechanisms, including scavenging oxidative stress, restoring immune homeostasis, and modulating the gut microbiota. Collectively, our findings highlight the promising potential of this innovative nanotherapeutic strategy for the targeted treatment of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease
Zhang, S., Ermann, J., Succi, M. D., Zhou, A., Hamilton, M. J., Cao, B., Korzenik, J. R., Glickman, J. N., Vemula, P. K., Glimcher, L. H., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5657 · Cited by 467
Zeng, F., Wu, Y., Li, X., Ge, X., Guo, Q., Lou, X., Cao, Z., Hu, B., Long, N. J., Mao, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802309 · Cited by 208
Cited by
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Zhang, X., Zhong, G., Peng, S., Zhang, C., Li, B., Xia, Z., Zhu, Y., Tao, G., Cai, R., & Xu, X. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02050 · Cited by 16
Self-citation
Metadata
- Authors
- Zhang, X., Yuan, Z., Wu, J., He, Y., Lu, G., Zhang, D., Zhao, Y., Wu, R., Lv, Y., Cai, K., & He, S.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-10-16
- Volume
- 17
- Issue
- 21
- Pages
- 21116-21133
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W4387661616
- Cited by
- 170
- References
- 3
- FWCI
- 24.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.